Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study

被引：10

作者：

Taoka, Rikiya ^{[1
]}

Kamada, Masaki ^{[2
]}

Izumi, Kazuyoshi ^{[3
]}

Tanimoto, Ryuta ^{[4
]}

Daizumoto, Kei ^{[5
]}

Hayashida, Yushi ^{[6
]}

Uematsu, Katsutoshi ^{[7
]}

Arai, Hironobu ^{[8
]}

Sano, Takeshi ^{[9
]}

Saito, Ryoichi ^{[10
]}

Hirama, Hiromi ^{[11
]}

Kobayashi, Toshihiro ^{[12
]}

Honda, Tomoko ^{[1
]}

Osaki, Yu ^{[1
]}

Abe, Yohei ^{[1
]}

Naito, Hirohito ^{[1
]}

Tohi, Yoichiro ^{[1
]}

Matsuoka, Yuki ^{[1
]}

Kato, Takuma ^{[1
]}

Okazoe, Homare ^{[1
]}

Ueda, Nobufumi ^{[1
]}

Sugimoto, Mikio ^{[1
]}

机构：

[1] Kagawa Univ, Fac Med, Dept Urol, 1750-1 Ikenobe, Miki, Kagawa, Japan

[2] Kagawa Univ, Dept Neurol Intractable Dis Res, Sch Med, Kita, Japan

[3] Takamatsu Red Cross Hosp, Dept Urol, Takamatsu, Japan

[4] Kagawa Prefectural Cent Hosp, Dept Urol, Takamatsu, Japan

[5] Tokushima Univ, Grad Sch Biomed Sci, Dept Urol, Tokushima, Japan

[6] Sakaide City Hosp, Dept Urol, Sakaide, Japan

[7] Mitoyo Gen Hosp, Dept Urol, Kanonji, Japan

[8] Shodoshima Cent Hosp, Dept Urol, Shodoshima, Japan

[9] Kansai Med Univ, Dept Urol, Hirakata, Japan

[10] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan

[11] KKR Takamatsu Hosp, Dept Urol, Takamatsu, Japan

[12] Kagawa Univ, Fac Med, Dept Endocrinol & Metab, Kita, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 29卷 / 05期

关键词：

Urothelial carcinoma; Enfortumab vedotin; Peripheral neuropathy; Nerve conduction study; CANCER;

D O I：

10.1007/s10147-024-02481-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundEnfortumab vedotin is a novel antibody-drug conjugate used as a third-line therapy for the treatment of urothelial cancer. We aimed to elucidate the effect of enfortumab vedotin-related peripheral neuropathy on its efficacy and whether enfortumab vedotin-induced early electrophysiological changes could be associated with peripheral neuropathy onset.MethodsOur prospective multicenter cohort study enrolled 34 patients with prior platinum-containing chemotherapy and programmed cell death protein 1/ligand 1 inhibitor-resistant advanced urothelial carcinoma and received enfortumab vedotin. The best overall response, progression-free survival, overall survival, and safety were assessed. Nerve conduction studies were also performed in 11 patients.ResultsThe confirmed overall response rate and disease control rate were 52.9% and 73.5%, respectively. The median overall progression-free survival and overall survival were 6.9 and 13.5 months, respectively, during a median follow-up of 8.6 months. The patients with disease control had significantly longer treatment continuation and overall survival than did those with uncontrolled disease. Peripheral neuropathy occurred in 12.5% of the patients. The overall response and disease control rates were 83.3% and 100%, respectively: higher than those in patients without peripheral neuropathy (p = 0.028 and p = 0.029, respectively). Nerve conduction studies indicated that enfortumab vedotin reduced nerve conduction velocity more markedly in sensory nerves than in motor nerves and the lower limbs than in the upper limbs, with the sural nerve being the most affected in the patients who developed peripheral neuropathy (p = 0.011).ConclusionOur results indicated the importance of focusing on enfortumab vedotin-induced neuropathy of the sural nerve to maximize efficacy and improve safety.

引用

页码：602 / 611

页数：10

共 19 条

[1] Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve [J].

Alberti, Paola ;

Rossi, Emanuela ;

Argyriou, Andreas A. ;

Kalofonos, Haralabos P. ;

Briani, Chiara ;

Cacciavillani, Mario ;

Campagnolo, Marta ;

Bruna, Jordi ;

Velasco, Roser ;

Cazzaniga, Marina E. ;

Cortinovis, Diego ;

Valsecchi, Maria G. ;

Cavaletti, Guido .

SUPPORTIVE CARE IN CANCER, 2018, 26 (09) :3143-3151

[2] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[3] Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy [J].

Best, Rebecca L. ;

LaPointe, Nichole E. ;

Azarenko, Olga ;

Miller, Herb ;

Genualdi, Christine ;

Chih, Stephen ;

Shen, Ben-Quan ;

Jordan, Mary Ann ;

Wilson, Leslie ;

Feinstein, Stuart C. ;

Stagg, Nicola J. .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 2021, 421

[4]

Bladder Cancer, 2023, NATL COMPREHENSIVE C

[5] Electrophysiological Features of Taxane-Induced Polyneuropathy in Patients With Breast Cancer [J].

Chen, Xi ;

Stubblefield, Michael D. ;

Custodio, Christian M. ;

Hudis, Clifford A. ;

Seidman, Andrew D. ;

DeAngelis, Lisa M. .

JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2013, 30 (02) :199-203

[6] Role of interdigital sensory nerve conduction study as a noninvasive approach for early diagnosis of diabetic peripheral neuropathy [J].

Fateh, Hamid R. ;

Madani, Seyed Pezhman .

JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2021, 20 (01) :71-75

[7] Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up [J].

Fradet, Y. ;

Bellmunt, J. ;

Vaughn, D. J. ;

Lee, J. L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D., I ;

Culine, S. ;

Sternberg, C. N. ;

Nam, K. ;

Frenkl, T. L. ;

Perini, R. F. ;

de Wit, R. ;

Bajorin, D. F. .

ANNALS OF ONCOLOGY, 2019, 30 (06) :970-976

[8] Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update [J].

Loprinzi, Charles L. ;

Lacchetti, Christina ;

Bleeker, Jonathan ;

Cavaletti, Guido ;

Chauhan, Cynthia ;

Hertz, Daniel L. ;

Kelley, Mark R. ;

Lavino, Antoinette ;

Lustberg, Maryam B. ;

Paice, Judith A. ;

Schneider, Bryan P. ;

Lavoie Smith, Ellen M. ;

Smith, Mary Lou ;

Smith, Thomas J. ;

Wagner-Johnston, Nina ;

Hershman, Dawn L. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (28) :3325-3348

[9] Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma [J].

Matsubara, Nobuaki ;

Yonese, Junji ;

Kojima, Takahiro ;

Azuma, Haruhito ;

Matsumoto, Hiroaki ;

Powles, Thomas ;

Rosenberg, Jonathan E. ;

Petrylak, Daniel P. ;

Matsangou, Maria ;

Wu, Chunzhang ;

Campbell, Mary ;

Yamashiro, Mayumi .

CANCER MEDICINE, 2023, 12 (03) :2761-2771

[10] Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J].

Powles, T. ;

Bellmunt, J. ;

Comperat, E. ;

De Santis, M. ;

Huddart, R. ;

Loriot, Y. ;

Necchi, A. ;

Valderrama, B. P. ;

Ravaud, A. ;

Shariat, S. F. ;

Szabados, B. ;

van der Heijden, M. S. ;

Gillessen, S. .

ANNALS OF ONCOLOGY, 2022, 33 (03) :244-258

← 1 2 →